



VICTORIA UNIVERSITY
MELBOURNE AUSTRALIA

Attempting to Compensate for Reduced Neuronal Nitric Oxide Synthase Protein with Nitrate Supplementation Cannot Overcome Metabolic Dysfunction but Rather Has Detrimental Effects in Dystrophin-Deficient mdx Muscle

This is the Accepted version of the following publication

Timpani, Cara, Trewin, Adam, Stojanovska, Vanesa, Robinson, Ainsley, Goodman, Craig, Nurgali, Kulmira, Betik, Andrew, Stepto, Nigel, Hayes, Alan, McConell, Glenn and Rybalka, Emma (2017) Attempting to Compensate for Reduced Neuronal Nitric Oxide Synthase Protein with Nitrate Supplementation Cannot Overcome Metabolic Dysfunction but Rather Has Detrimental Effects in Dystrophin-Deficient mdx Muscle. *Neurotherapeutics*, 14 (2). 429 - 446. ISSN 1933-7213

The publisher's official version can be found at
<http://link.springer.com/article/10.1007/s13311-016-0494-7>
Note that access to this version may require subscription.

Downloaded from VU Research Repository <https://vuir.vu.edu.au/33568/>

Article Type

Original Research Article

Title

Attempting to compensate for reduced nNOS protein with nitrate supplementation cannot overcome metabolic dysfunction but rather has detrimental effects in dystrophin-deficient *mdx* muscle

Author Names & Affiliations

Cara A Timpani*, Adam J Trewin†, Vanesa Stojanovska*, Ainsley Robinson*, Craig A Goodman*†‡, Kulmira Nurgali*, Andrew C Betik*†, Nigel Stepto†, Alan Hayes*†‡, Glenn K McConell†‡, Emma Rybalka*†‡

*Centre for Chronic Disease, College of Health & Biomedicine, Victoria University, Melbourne, Victoria, 8001, Australia

†Institute of Sport, Exercise & Active Living (ISEAL), Victoria University, Melbourne, Victoria, 8001 Australia

‡Australian Institute of Musculoskeletal Science (AIMSS), Western Health, Melbourne, Victoria, 3021 Australia

Contact

Dr Emma Rybalka

+ 61 3 83958226

emma.rybalka@vu.edu.au

Running Head

Nitrate supplementation in the *mdx* mouse

Summary

Duchenne Muscular Dystrophy arises from the loss of dystrophin and is characterised by Ca^{2+} dysregulation, muscular atrophy and metabolic dysfunction. The secondary reduction of neuronal nitric oxide synthase (nNOS) from the sarcolemma reduces NO production and bioavailability. As NO modulates glucose uptake, metabolism and mitochondrial bioenergetics, we investigated whether an 8 week nitrate supplementation regimen could overcome metabolic dysfunction in the *mdx* mouse. Dystrophin-positive control (C57BL/10) and dystrophin-deficient *mdx* mice were supplemented with sodium nitrate (85mg.L^{-1}) in drinking water. Following the supplementation period, extensor digitorum longus and soleus were excised and radioactive GU was measured at rest (basal) and during contraction. Gastrocnemius was excised and mitochondrial respiration was measured using the Oroboros Oxygraph. Tibialis anterior was immunohistochemically analysed for the presence of dystrophin, nNOS and nitrotyrosine and histologically analysed to assess areas of damage and regeneration. Basal and contraction-induced glucose uptake was lower in dystrophic muscle and could not be rescued with nitrate supplementation. The mitochondrial utilisation of substrates was also impaired in *mdx* gastrocnemius during phosphorylating and maximal uncoupled respiration and nitrate could not improve respiration in *mdx* muscle. Although nitrate supplementation reduced mitochondrial hydrogen peroxide emission, it induced mitochondrial uncoupling in red gastrocnemius, increased muscle fibre peroxynitrite (nitrotyrosine) and promoted skeletal muscle damage. Our novel data suggests that despite lower nNOS protein expression and likely lower NO production in *mdx* muscle, enhancing NO production with nitrate supplementation in these mice has detrimental effects on skeletal muscle. This may have important relevance for those with DMD.

Keywords

Duchenne Muscular Dystrophy, nitrate supplementation, metabolism, glucose uptake, mitochondria

Introduction

Duchenne Muscular Dystrophy (DMD) is a progressive X-linked [1] neuromuscular disease affecting 1 in 3,500-5,000 live male births [2], which arises from the ablation of the cytoskeletal protein, dystrophin [3]. Dystrophin deficiency causes alterations to the myofibre architecture leading to membrane lesions, calcium (Ca^{2+}) accumulation, muscular weakness and cyclic bouts of degeneration and regeneration until the regenerative capacity of the muscle is unable to match demand for repair [4]. Damaged muscle is eventually replaced with fibrous and/or fatty connective tissue leading to a decrease in muscle function, with cardiorespiratory failure ensuing by the third decade of life [5].

Mitochondrial and metabolic dysfunction have been increasingly implicated in the pathogenesis of DMD although it is not known if these abnormalities are associated with dystrophin deficiency, the pathophysiological sequelae caused by dystrophin deficiency, or completely independent of dystrophin deficiency [6]. Indeed, the only obvious physical link between dystrophin and the intracellular metabolic pathways is via neuronal nitric oxide synthase (nNOS) whereby ablation of dystrophin from the sarcolemma induces the secondary loss of the dystrophin-associated proteins [7] including nNOS [8, 9]. nNOS produces NO, a key signalling molecule in skeletal muscle that regulates various biological processes including blood flow, contraction, mass, satellite cell activation, Ca^{2+} handling and glucose uptake (GU), in addition to mitochondrial metabolism, gene expression and reactive oxygen species (ROS) production [10]. In dystrophic muscle, the dissociation of nNOS from the sarcolemma results in reduced nNOS content [11, 12, 13, 14], activity [9, 15, 16] and NO production [17, 18, 19]. Importantly, this loss of nNOS has been shown to contribute to the progression of the dystrophic condition and to the deficits in metabolic function. For example, nNOS is a positive allosteric regulator of phosphofructokinase (PFK), the rate limiting enzyme of the glycolytic pathway [20], and therefore plays a critical role in regulating glucose metabolism. Interestingly, DMD is not only associated with impairments in glycolysis [20, 21, 22] but also in β -fatty acid oxidation, the tricarboxylic acid cycle (TCA) and the electron

transport system (ETS) (for detailed reviewed see [6]). Collectively, these metabolic impairments result in reduced energy production [23], with reports of ATP content being 50% lower under resting conditions [24, 25]. Given that nNOS localisation and NO signalling are known to be important for metabolic control, the loss of nNOS and NO bioavailability might be key to metabolic deregulation in dystrophic skeletal muscle. Therefore, increasing NO availability has the potential to be of therapeutic benefit.

In an attempt to normalise NO production, several studies have reintroduced nNOS into dystrophic skeletal muscle which demonstrably reduces muscle damage and inflammation [26, 27]. As gene therapy for nNOS transfection is not yet available in humans, other strategies to restore NO availability have been investigated. Several studies have shown that supplementation with NO donors, often combined with anti-inflammatory drugs, results in reduced damage, necrosis and inflammation and improved muscle blood flow, function/strength and repair [28, 29, 30, 31, 32, 33, 34, 35] in dystrophin-deficient skeletal muscle. While these findings may suggest a positive effect of increasing NO availability, it is difficult to control the delivery of NO to the skeletal muscle with pharmacological donors and also to separate the effects of the NO donor from those of the anti-inflammatory co-treatment. Another approach to increase NO availability has been to supplement with the nNOS substrate, L-arginine [19]; however, the potential for L-arginine to increase NO production is limited by the lowered nNOS protein in dystrophic skeletal muscle. An alternative method to increase NO availability, that is independent of nNOS activity, is supplementation with nitrate (NITR). Specifically, dietary NITR can be reduced to nitrite by commensal bacteria of the oral cavity and gastrointestinal tract, with nitrite being subsequently reduced to NO via several enzymatic pathways in the blood and tissues [36]. This mechanism is complementary to NOS-derived NO production and, importantly, represents a pathway that could be exploited to increase NO availability in dystrophic muscle.

To date, no studies have investigated the effect of NITR supplementation on metabolic function in dystrophic muscle; however, recent studies suggest that NITR supplementation has the potential to improve metabolic function in skeletal muscle. For example, Larsen *et al.* [37] demonstrated that NITR supplementation in healthy, young males led to increased plasma NO concentration and subsequently, downstream metabolic adaptations including increased mitochondrial efficiency, reduced proton leak and ultimately increased ATP production capacity. Similar data has been derived in rats during fatty acid oxidation [38]. In addition, there is some evidence that NITR supplementation can increase exercise efficiency in humans [39, 40, 41] and exercise capacity in some disease conditions such as peripheral arterial disease, where NO production is reduced [42]. Most pertinently, increasing NO bioavailability through administration of sodium nitrite mitigates functional ischemia in Becker Muscular Dystrophy patients [43] suggesting that expansion of the NITR-nitrite-NO pool in DMD may also be beneficial. The results from these studies prompted us to investigate whether increasing NO availability via NITR supplementation, which has been previously proven to increase plasma [37, 44] and skeletal muscle [38] NO levels and elicit beneficial mitochondrial adaptations at the skeletal muscle level [37, 44], would improve mitochondrial function and rectify energy homeostasis dysregulation in dystrophic muscle. Therefore, we investigated whether an established dietary NITR supplementation regimen [44] could improve GU, mitochondrial function, ROS emission and muscle architecture in healthy (control; CON) and dystrophic (*mdx*) mouse models. We hypothesised that NITR supplementation would (1) increase GU in the contracting muscles from CON and *mdx* mice; (2) improve mitochondrial function in *mdx* mice and; (3) improve the muscle architecture of *mdx* mice.

Materials and Methods

Ethical approval

All experimental procedures were approved by the Victoria University Animal Ethics Experimentation Committee and conformed to the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes.

Animals and supplementation

Three week-old male C57Bl/10ScSn (normal wild-type strain; CON) and C57Bl/10*mdx* (*mdx*) mice were purchased from Animal Resources Centre (Western Australia, Australia) and housed at the Western Centre for Health, Research and Education (Sunshine Hospital, Victoria, Australia) on a 12:12 hour light-dark cycle with *ad libitum* access to food and water. Following a one week acclimatisation period, mice were randomly assigned into four groups: unsupplemented (CON UNSUPP and *mdx* UNSUPP) and supplemented (CON NITR and *mdx* NITR). Mice in the supplemented groups were given 85 mg.L⁻¹ (1mM) sodium NITR [44] *ad libitum* in drinking water for 8 weeks and mice in the unsupplemented groups were given drinking water without NITR. The dose of NITR is comparable to doses studied in human experiments, is achievable through a normal diet [45], and is proven to increase the plasma NITR-nitrite-NO pool [37, 44].

Materials and antibodies

All chemicals, unless stated otherwise, were purchased from Sigma-Aldrich Chemicals (St. Louis, MO). 2-Deoxy-D-[1,2-³H]glucose and D-[¹⁴H]mannitol were purchased from Perkin Elmer (Waltham, MA, USA). Dystrophin (ab15277), nNOS (ab1376), nitrotyrosine (ab42789) and Total OXPHOS (ab110413) primary antibodies were purchased from Abcam (MA, USA). Secondary antibodies for immunohistochemistry were purchased from Jackson ImmunoResearch Laboratories (PA, USA) and for western blotting from Vector Laboratories (Burlingame, CA, USA).

Muscle dissection and contraction protocol

Mice were deeply anaesthetised via intraperitoneal injection of sodium pentobarbitone (60mg/kg) and the white extensor digitorum longus (EDL) and red soleus (SOL) muscle proximal and distal tendons in each hind limb were tied with 4/0 surgical silk. Both EDL and SOL were surgically dissected tendon-to-tendon and placed into individual muscle baths containing Krebs basal buffer (118.5mM NaCl, 24.7mM NaHCO₃, 4.74mM KCl, 1.18mM MgSO₄, 2.5mM CaCl₂, 8mM mannitol, 2mM Na pyruvate, 0.01% BSA; pH 7.4) bubbled with carbogen (95% O₂, 5% CO₂) at 30°C. The proximal tendon was attached to a force transducer and muscles were rested for 20 minutes to equilibrate in the bath. Muscles were stimulated via square wave electrical pulses delivered by platinum electrodes flanking the muscles, and subsequent recording of the force output were obtained from a custom-built muscle analysis system (Zultek Engineering, Victoria, Australia). Following determination of optimal length (L_o) for each muscle via a succession of isometric twitch contractions, the left EDL and SOL were stimulated to contract for a total of 10 minutes (pulse durations of 350msec and 500msec for EDL and SOL, respectively at a frequency of 60 Hz). This protocol maintains muscle viability and maximises GU [46]. The right EDL and SOL were not stimulated in order to measure basal GU.

Glucose uptake

Following 5 minutes of contraction, the Krebs basal buffer was exchanged for Krebs buffer with 2-Deoxy-D-[1,2-³H]glucose (0.128μCi/mL) and D-[¹⁴H]mannitol (0.083μCi/mL) in both resting and contracting muscles. At the end of the 10 minute contraction protocol, muscles were immediately submerged in ice-cold Krebs basal buffer to stop further glucose uptake, blotted on filter paper and snap frozen in liquid nitrogen. Whole muscles were weighed frozen, digested for 10 minutes at 95°C in 135μL of 1M NaOH, neutralised with 135μL of 1M HCl and centrifuged for 5 minutes at 13,000g. 200μL of supernatant was added to 4mL of inorganic scintillation fluid (UltimaGold, Perkin Elmer) and radioactivity was

measured in a β -scintillation counter (Tri-Carb 2810, Perkin Elmer). GU was calculated [47] and corrected for sPo as described previously [48].

Mitochondrial respiration and hydrogen peroxide emission measurements

Left and right gastrocnemius were excised from the anaesthetised mice, separated into RG and WG portions and immediately placed into ice-cold BIOPS (7.23mM K₂EGTA, 2.77mM CaK₂EGTA, 5.77mM Na₂ATP, 6.56mM MgCl₂-6H₂O, 20mM taurine, 15mM phosphocreatine, 20mM imidazole, 0.5mM dithiothreitol, 50mM K⁺-MES; pH 7.1). Muscle fibres were mechanically separated from a small portion of muscle in ice-cold BIOPS to maximise fibre surface area and transferred into ice-cold BIOPS supplemented with saponin (50 μ g/mL) for 30 minutes. Separated fibres were agitated to permeabilise the sarcolemma and allow diffusion of subsequent assay substrates, and then washed three times via agitation in ice-cold respiration buffer (110mM K⁺-MES, 35mM KCl, 1mM EGTA, 5mM K₂HPO₄, 3mM MgCl₂-6H₂O, 0.05mM pyruvate, 0.02mM malate, 5 mg/mL BSA; pH 7.4). Fibre bundles were then divided and weighed on a microbalance (2-4 mg each) for subsequent respirometry analysis in duplicate.

ETS respiration, OXPHOS and H₂O₂ emission were measured by the Oxygraph O2k high resolution respirometer (Oroboros Instruments, Innsbruck, Austria) via a substrate, uncoupler, inhibitor titration (SUIT) protocol at 37°C in MIR05 respiration medium while stirring at 750 rpm as previously described [49, 50], with minor modifications in order to assess H₂O₂ emission. Briefly, after fibres and oxygen (O₂) were added to the respiration chamber, the SUIT protocol commenced with titrations of the complex I (CI) substrates malate (2mM final concentration) and pyruvate (10mM), followed by the complex II (CII) substrate succinate (10mM) to determine leak (state 4) respiration. Titrations of ADP (0.25, 1 and 5mM) assessed OXPHOS (state 3) capacity, addition of cytochrome c (10 μ M) tested mitochondrial membrane integrity and titrations of FCCP (0.025 μ M) determined uncoupled respiration. Complex-specific respiration was inhibited by the addition of rotenone (1 μ M) and

antimycin A (5 μ M) to CI and complex III (CIII), respectively. Finally, complex IV (CIV) capacity was measured during oxidation of TMPD (0.5mM) with ascorbate (2mM). The O₂ flux due to autoxidation of these chemicals was determined after inhibition of CIV with sodium azide (75 mM) then subtracted from the raw CIV O₂ flux.

Mitochondrial H₂O₂ emission was simultaneously measured in the respiration chamber throughout the SUIT protocol via optical sensors (O2k-Fluorescence LED-2 Module, Oroboros, Austria) as previously described [51, 52, 53]. Superoxide (O₂⁻) produced during the SUIT protocol was converted to H₂O₂ due to the presence of a saturating concentration of O₂⁻ dismutase (2.5 U.mL⁻¹), and the subsequent H₂O₂ generation was quantified via the reaction of Amplex UltraRed (25 μ M; Molecular Probes, Invitrogen) with horseradish peroxidase (2.5 U.mL⁻¹) at excitation/emission 565/600 nm wavelength. The H₂O₂ detection chemicals were added to the chambers containing MIR05 respiration medium at the beginning of the experiment, prior to the addition of the muscle fibres.

Chamber O₂ concentration was maintained between 300-450 nmol.ml⁻¹. Mass specific O₂ flux and H₂O₂ emission was determined from steady-state flux normalised to tissue wet weight and adjusted for instrumental background and residual O₂consumption. Respiratory control ratios were calculated (complex specific O₂ flux relative to maximal uncoupled ETS respiration) to investigate intrinsic mitochondrial function independent of mitochondrial density.

Western blot analysis of mitochondrial respiratory chain proteins

Frozen tissues were homogenised for 20 seconds in ice-cold WB buffer (40 mM Tris, pH 7.5; 1 mM EDTA; 5 mM EGTA; 0.5% Triton X-100; 25 mM β -glycerophosphate; 25 mM NaF; 1 mM Na₃VO₄; 10 μ g/ml leupeptin; and 1 mM PMSF), and the whole homogenate was used for further analysis. Sample protein concentrations were determined with a DC protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA), and equivalent amounts of protein (15 μ g) from each sample were dissolved in Laemmli buffer, heated for 5 min at 37°C and

subjected to electrophoretic separation on SDS-PAGE acrylamide gels. Following electrophoretic separation, proteins were transferred to a PVDF membrane, blocked with 5% powdered milk in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1 h followed by an overnight incubation at 4°C with primary antibody dissolved in TBST containing 1% bovine serum albumin (BSA). The Total OXPHOS Antibody Cocktail (1:1000), which detects representative proteins from each of the five mitochondrial respiratory chain complexes, was obtained from Abcam. This cocktail consisted of primary antibodies against the following proteins: NADH Dehydrogenase (Ubiquinone) 1 Beta Sub-complex, 8 (NDUFB8; CI), Succinate Dehydrogenase Assembly Factor 4 (SDH8; CII), Ubiquinol-Cytochrome-C Reductase Complex Core Protein 2 (UQCRC2; Complex III; CIII), Mitochondrially Encoded Cytochrome C Oxidase I (MTOC1; Complex IV; CIV) and Mitochondrial ATP Synthase Subunit Alpha (ATPSA; Complex V; CV). After overnight incubation, the membranes were washed for 30 min in TBST and then probed with a peroxidase-conjugated secondary antibody (1:10000, anti-mouse, Vector Labs) for 1 h at room temperature. Following 30 min of washing in TBST, the blots were developed with a DARQ CCD camera mounted to a Fusion FX imaging system (Vilber Lourmat, Germany) using ECL Prime reagent (Amersham, Piscataway, NJ, USA). Once the images were captured, the membranes were stained with Coomassie Blue to verify equal loading of total protein in all lanes. Densitometric measurements were carried out using Fusion CAPT Advance software (Vilber Lourmat, Germany).

Citrate Synthase Activity

Homogenised RG and WG samples were utilised to measure citrate synthase (CS) activity as a marker of mitochondrial density [54, 55]. Homogenised samples were added to reagent cocktail (100 mM Tris Buffer, 1 mM DTNB, 3 mM Acetyl CoA) and CS activity was measured spectrophotometrically (412nm at 25°C) for 5 minutes following the addition of 10mM oxaloacetate as described previously [23]. CS activity was calculated using the

extinction coefficient of 13.6 [56]. CS activity was normalised to whole muscle protein concentration.

Histological Analysis

Following excision, the right TA was frozen in liquid nitrogen-cooled isopentane and optimal cutting temperature compound (Sakura Finetek). Embedded TA's were cryo-sectioned (10µm) at -20°C using a Leica (CM1950) cryostat and mounted onto glass slides (Menzel-Glaser).

Dystrophin and nNOS Immunolabelling

Slides were fixed using a Cytotfix/Cytoperm Plus kit (BD Biosciences) for 5 minutes. After incubation with blocking serum (0.1M PBS, 0.1% triton, 10% FBS) for 1 hour at room temperature, sections were labelled with primary antibodies: rabbit anti-dystrophin (1:400) and goat anti-nNOS (1:200) overnight at room temperature. After washing three times with a 0.1M PBS and 0.1% triton X solution, samples were incubated with secondary antibodies: donkey anti-rabbit Alexa 488 (1:200) and donkey anti-goat Alexa 594 (1:200) for 2 hours at room temperature. Tissues were washed three times with a 0.1M PBS and 0.1% triton X solution and mounted with fluorescent mounting medium (DAKO, Australia). Confocal microscopy was performed on an Eclipse Ti confocal laser scanning system (Nikon, Japan). Fluorophores were visualized using a 488 nm excitation filter for Alexa 488 or FITC and a 559 nm excitation filter for Alexa 594 or Rhodamine Red. Z-series images were acquired at a nominal thickness of 0.5µm (512x512 pixels). The density of dystrophin and nNOS immunoreactivity in TA sections was measured from eight randomly captured images (total area size 2mm²) per animal at 20x magnification. All images were captured under identical acquisition exposure time conditions and calibrated to standardised minimum baseline fluorescence. Images were converted from red, green, and blue (RGB) to grayscale 8 bit then to binary; changes in fluorescence from the baseline were measured using Image J

software (NIH, USA). The area of immunoreactivity was then expressed as a percentage of the total area examined. Quantitative analyses were conducted blindly.

Nitrotyrosine, CD45 and IgG Immunolabelling

Slides were fixed with 4% formaldehyde for 30 minutes at room temperature. After incubation with blocking serum (0.1M PBS, 0.1% triton, 10% donkey serum) for 1 hour at room temperature, sections were then labelled with primary anti-S-nitrotyrosine (rabbit; 1:200; Millipore), anti-CD45 (pan-leukocyte marker; rat; 1:200) and anti-IgG isotype control (hamster; 1:200) primary antibodies overnight at room temperature. After washing three times with a 0.1M PBS and 0.1% triton X solution, samples were incubated with the appropriate secondary antibody (anti-rabbit Alexa Fluor 647, 1:100, Abacus ALS, UK; anti-rat Alexa Fluor 488, Jackson Immuno Research; anti-hamster Alexa Fluor 594, Jackson Immuno Research) for 2 hours at room temperature. A pan nuclei marker DAPI (4',6-diamidino-2-phenylindole) was added to the tissue sections and incubated for 2 minutes at room temperature, tissues were washed three times with a 0.1M PBS and 0.1% triton X solution and mounted with an anti-fade fluorescent mounting medium. Excitation wavelengths were set to 640nm for Alexa 647, 406nm for Alexa 405, 408.8nm for Alexa Fluor 488 and 561.8nm for Alexa Fluor 594. The confocal microscope was calibrated to standardise the minimum baseline fluorescence for imaging nitrotyrosine, CD45 and IgG immunoreactivity in the TA cross sections. At time of analysis all files were converted to thresholded 8-bit binary images using ImageJ software from eight randomly captured images per animal. Images were analysed through the 'analyze particles' function, recording the counts (to determine the number of DAPI positive nuclei) and relative nitrotyrosine expression recorded as percentage area fraction in arbitrary units. Green pseudocolor images of nitrotyrosine (Alexa Fluor 647; magenta) were generated using ImageJ software for publication only.

Haematoxylin & Eosin Staining

Slides were air-dried and stained using a haematoxylin and eosin (H&E) staining protocol including a 30 second incubation in haematoxylin and a 1 minute and 45 second incubation in eosin. Slides were imaged using a Zeiss Axio Imager Z2 microscope at 20x magnification. Fibre size, damaged area (areas of myofibril demise and inflammatory cell infiltration [57]) and fibres with centralised nuclei were determined using ImageJ software.

Statistics

Results are presented as mean \pm standard error of the mean. For all data, except for GU, a two-way ANOVA was utilised to detect between strain/genotype (CON vs. *mdx*) and supplementation (UNSUPP vs. NITR) differences. For GU data, a three-way ANOVA was performed for each of EDL and SOL to detect between strain, supplementation and GU type (basal vs. contraction). When a main effect or an interaction was detected, unpaired T-tests were used to determine differences between individual groups using SPSS (version 21). An α value of 0.05 was considered significant.

Results

Effect of NITR supplementation on body weight, food and water consumption and muscle weights

Throughout the 8 week supplementation period, greater weight gains were observed in the *mdx* groups compared to CON ($p<0.0001$; Figure 1A), with NITR having no effect in *mdx* mice ($p>0.05$). NITR did, however, stimulate weight gain in CON ($p<0.05$). No significant difference in food or water consumption was observed between any group over the supplementation period (Figure 1B & C respectively; $p>0.05$) except at week two where food consumption was greater in CON UNSUPP compared to all groups ($p<0.05$, Figure

1B). Overall, individual hind limb muscle weights were greater in the *mdx* compared to CON strain ($p<0.0001$; Table 1 and 2) with NITR having no effect ($p>0.05$).

Immunolabelling of dystrophin and nNOS

To confirm the deficiency of both dystrophin and nNOS in *mdx* skeletal muscle, the presence of dystrophin and nNOS protein (Figure S1) was determined in the TA. Indeed, dystrophin was only evident in CON TA (Figure S1A and C) and was absent from *mdx* TA except for a few spontaneously revertant fibres ($p<0.0001$). Similarly, nNOS was only evident in CON TA (Figure S1A^I and C^I) and was completely absent from dystrophin-deficient *mdx* fibres ($p<0.0001$). Co-localisation of dystrophin and nNOS was only observed in CON (Figure S1A^{II} and C^{II}) and NITR had no effect on either dystrophin or nNOS expression ($p>0.05$).

Effect of NITR supplementation on glucose uptake

NO has been proposed to play a role in contraction-stimulated GU and as such, we first investigated the effect of NITR supplementation on GU in CON and *mdx* muscles. This is the first instance of contraction-induced GU being measured in the *mdx* mouse and we demonstrated no difference in basal- or contraction-induced GU between CON and *mdx* UNSUPP EDL ($p>0.05$, Figure 2A). As expected, contraction induced an increase in GU in the EDL's of CON UNSUPP (55%), CON NITR (61%), *mdx* UNSUPP (35%) and *mdx* NITR (51%) compared to basal conditions ($p<0.05$, Figure 2A). NITR supplementation significantly increased contraction-induced GU in CON EDL muscles ($p<0.05$; Figure 2A) however in contrast, NITR reduced both basal- and contraction-induced GU in *mdx* muscles ($p<0.05$; Figure 2A). Contrary to the EDL, contraction did not stimulate further GU beyond that observed in basal conditions for any group in the SOL (all less than 20%, $p>0.05$, Figure 2B). While NITR had no effect on basal or contraction-induced GU in CON SOL muscles ($p>0.05$; Figure 2B), NITR further reduced both basal and contraction-induced GU in *mdx* SOL muscles ($p<0.05$). Combined, these data suggest that NITR supplementation has a

negative effect on GU in both *mdx* EDL and SOL which may lead to impairments in downstream glycolysis and oxidative metabolism.

Effect of NITR supplementation on mitochondrial function

Respirometry

Next, we examined the effect of NITR on parameters of mitochondrial function. First, we measured state 4 leak respiration which, in the absence of ADP, indicates the contribution of proton leak to respiration. In the presence of pyruvate and malate (CI), state 4 leak respiration was significantly lower in *mdx* white (WG) ($p<0.05$; Figure 3A) and red gastrocnemius (RG) ($p<0.01$; Figure 3C) muscles compared to their respective controls. In the presence of pyruvate, malate and succinate (CI+II), state 4 leak respiration was significantly higher than CI respiration across all groups, in both WG and RG muscles ($p<0.0001$; Figure 3A and 3C, respectively). NITR supplementation had no effect on either CI or CI+II state 4 leak respiration in CON or *mdx* muscles (Figure 3A and 3C).

Next, the effect of NITR on coupled OXPHOS capacity was examined in WG and RG muscles by assessing maximal ADP-stimulated state 3 respiration in the presence of excess malate, pyruvate and succinate (complex I and II (CI+II) substrates). As shown in Figure 3, state 3 respiration was significantly depressed in *mdx* WG by ~15% ($p<0.05$; Figure 3A) and in *mdx* RG by 25% ($p<0.001$; Figure 3C) compared to CON. NITR supplementation, however, had no effect on State 3 respiration in either muscle (Figure 3A and 3C).

Maximal ETS capacity was then assessed by the addition of the uncoupling agent FCCP, which dissipates the mitochondrial membrane potential ($\Delta\Psi$). This parameter gives an indication of the maximal respiration in the uncoupled state. FCCP-induced maximal uncoupled respiration was significantly lower in *mdx* WG ($p<0.05$; Figure 3A) and RG ($p<0.001$; Figure 3C) compared to their respective controls; however, there was no effect of NITR on this parameter.

Next, we measured the activity of CIV (cytochrome C oxidase), the terminal oxidase of the ETS and the site of O₂ reduction to water. As shown in Figure 3, CIV activity was not different between UNSUPP CON and *mdx* WG muscles (Figure 3A); however, in the RG muscles, CIV activity was significantly lower in *mdx* UNSUPP compared to CON UNSUPP ($p<0.01$; Figure 3C). NITR induced a significant increase in CIV activity in CON WG muscles ($p<0.01$; Figure 3A) but reduced CIV activity in both CON and *mdx* RG muscles ($p<0.01$; Figure 3C).

Finally, the respiratory control ratio (state 3 respiration divided by state 4 respiration; RCR) was calculated. The RCR is an indicator of the extent to which O₂ consumption is coupled to ATP production and therefore mitochondrial efficiency, with a higher RCR indicating better coupling. No difference in RCR was observed between CON and *mdx* WG ($p>0.05$, Figure 5B). In *mdx* RG respiring on CI+II, the RCR was significantly lower compared to CON ($p<0.0001$) and NITR decreased the RCR further ($p<0.01$, Figure 3D). This highlights that in oxidative red muscle at least, *mdx* mitochondria are more uncoupled and that this uncoupling is exacerbated by NITR.

Electron Transport Chain Complex Expression

To determine whether the genotypic differences and NITR supplementation-induced changes in respiration parameters were associated with differences in mitochondrial ETS complex densities, the abundance of representative proteins from each of the five ETS complexes were measured using semi-quantitative Western blotting (Figure 4 and 5). In WG muscles, despite state 3, state 4 and maximal uncoupled respiration being lower in *mdx* muscles (Figure 3A), the relative abundance of representative proteins from complexes I to V were not lower. In fact, to the contrary, proteins from CII, CIII, CIV and CV were significantly elevated in *mdx* UNSUPP WG muscles compared to CON UNSUPP muscles (Figure 4). Interestingly, the NITR-induced increase in CIV respiratory activity (Figure 3A) was not associated with a significant increase in the abundance of the CIV protein (Figure

4D). NITR supplementation did, however, lead to an increase in representative proteins in WG muscles for CI, CII, CIII and CV in CON but not *mdx* muscles (Figure 4).

Unlike the WG muscles, the lower state 3, state 4, uncoupled respiration and CIV activity found in RG *mdx* muscles (Figure 3C) was accompanied by a reduction in representative proteins for CI, CII, CIV and CV compared with CON; however, NITR supplementation had no effect on any of these proteins in either CON or *mdx* RG muscles (Figure 5).

Citrate Synthase Activity

Finally, we measured citrate synthase (CS) activity in WG and RG muscles as a co-marker of mitochondrial content alongside mitochondrial ETC proteins [58] (Figure 4F and 5F, respectively). As shown in Figure 4F, there was a trend for CS activity to be higher in *mdx* UNSUPP compared to CON UNSUPP WG muscles. Moreover, NITR increased CS activity in both CON and *mdx* WG muscles. In the RG muscles there was no difference in CS activity between UNSUPP CON and *mdx* mice; however, NITR increased CS activity in RG muscles from *mdx* mice. Overall, NITR did not improve the capacity to phosphorylate ATP or maximal respiratory capacity in dystrophic muscle despite increasing CS activity, suggesting that NITR may have an alternative effect on mitochondrial function such as ROS generation.

Effect of NITR supplementation on ROS production in red and white gastrocnemius

The effect of NITR supplementation on the production of the mitochondrial ROS superoxide (O_2^-), was measured in intact and permeabilised fibres from WG and RG simultaneously with respiration. In the presence of excess O_2^- dismutase, O_2^- is converted to hydrogen peroxide (H_2O_2), which reacts with Amplex Red to produce the red fluorescent product, resorufin. During state 3 respiration, no differences in H_2O_2 emission was detected between CON and *mdx* UNSUPP WG ($p>0.05$; Figure 6A) with NITR having no effect in

either strain ($p>0.05$; Figure 6A). NITR did, however, induce a decrease in H_2O_2 emission during state 4 leak respiration in CON WG muscle fibres respiring on CI substrates ($p<0.05$; Figure 6A). When respiring on CI+CII substrates, there was significantly greater H_2O_2 emission in all groups during state 4 leak respiration compared to CI substrates only in WG fibres ($p<0.0001$; Figure 6A). Importantly, NITR significantly decreased H_2O_2 emission in both CON and *mdx* WG muscles respiring during state-4 while on CI+II substrates ($p<0.05$; Figure 6A). There was no difference in H_2O_2 emission in WG between any groups during FCCP-stimulated maximal uncoupled respiration ($p>0.05$; Figure 6A).

In *mdx* RG fibres, there was significantly less H_2O_2 emission during state 3 respiration ($p<0.05$; Figure 6B) compared to CON fibres; however, there was no effect of NITR on this parameter ($p>0.05$). Similar to WG fibres, H_2O_2 emission was higher when respiring on CI+CII substrates compared to CI substrates across all groups during state 4 leak respiration ($p<0.0001$), however, NITR only reduced H_2O_2 emission in *mdx* fibres ($p<0.001$; Figure 6B). NITR also reduced H_2O_2 emission in *mdx* RG fibres during FCCP uncoupled respiration ($p<0.05$; Figure 6B). While our data suggests that NITR reduces mitochondrial ROS production in dystrophic muscle, it is possible that increased NO bioavailability may sequester O_2^- from the O_2^- dismutase reaction to increase reactive nitrogen species (RNS).

Effect of NITR supplementation on peroxynitrite production, CD45-positive(+) infiltration and IgG immunolabelling

NO is known to rapidly react with O_2^- resulting in the production of the highly RNS, peroxynitrite ($ONOO^-$), and given that elevated ROS is present in *mdx* muscle [59], we investigated whether $ONOO^-$ production could account for the reduced H_2O_2 emission observed in our study. Increased $ONOO^-$ can result in increased protein nitration of tyrosine residues, potentially leading to altered protein function. Therefore, as an indirect marker of oxidative/nitrosative stress, we measured the effect of NITR on levels of nitrotyrosine via

immunohistochemical staining of TA muscles. *Mdx* muscles had significantly higher nitrotyrosine staining compared to CON muscles ($p<0.0001$) and NITR increased nitrotyrosine staining in both CON ($p<0.05$) and *mdx* ($p<0.0001$) TA (Figure 7A). Importantly, NITR inducing a dramatically greater increase in nitrotyrosine production in *mdx* muscles (2775% increase compared to 82% increase in CON). Additionally, NITR further increased the presence of DAPI-stained nuclei in NITR supplemented *mdx* TA ($p<0.0001$, Figure 7B). To assess if the increased nitrotyrosine staining was associated with increased inflammation, we measured CD45+ immune cell infiltration and IgG via immunolabelling. In *mdx* TA, both CD45+ and IgG+ area was elevated compared to CON muscles ($p<0.001$ and $p<0.01$ respectively, Figure 7C and D respectively). In contrast to nitrotyrosine staining, NITR had no effect on the CD45+ and IgG+ area in either strain ($p>0.05$).

Effect of NITR supplementation on muscle architecture

Finally, we assessed the effect of NITR on muscle fibre histopathology. As expected, intact *mdx* muscle fibres were significantly larger than fibres from CON muscles (Figures 8A and C) which is representative of pseudohypertrophy, a hallmark histopathological feature of dystrophin-deficient muscle. Interestingly, there was a strong trend for NITR supplementation to increase the number of fibres between 6000 and 7499 μm^2 ($p=0.068$; Figure 8A) and increase total mean fibre size ($p=0.093$; Figure 8C). The area of damage, as indicated by areas of inflammatory cell/nuclei infiltration, was significantly higher in *mdx* ($p<0.01$; Figure 8D) compared to CON TA sections and NITR significantly increased the damage area in *mdx* muscle ($p<0.01$). Centronucleated fibres, a marker of muscle cell regeneration, were significantly higher in *mdx* muscle ($p<0.0001$; Figure 8E) with NITR further increasing regeneration area in *mdx* sections ($p<0.01$). These results show that NITR supplementation enhances muscle damage, but also regeneration, in *mdx* TA but not in CON, which seems reflective of the increased ONOO⁻ production.

Discussion

This is the first study to date to investigate NITR supplementation as a potential therapy for DMD and we show that the metabolic perturbations in dystrophin-deficient skeletal muscle could not be overcome by enhancing nNOS-independent NO production. Instead, our data suggests that chronically increasing NO bioavailability without restoring nNOS protein expression and its regulatory role on metabolism, in fact, promotes pathological muscle damage, potentially via a peroxynitrite (ONOO⁻)-dependent mechanism.

In the first instance we investigated if impaired macronutrient uptake may be a contributing factor to the mitochondrial dysfunction in dystrophic muscle, as compromised transport of substrates across the sarcolemma could be a consequence of the loss of dystrophin and nNOS from the membrane. Specifically, we have investigated glucose uptake (GU) as it is well established that GU during rest and contraction is regulated by NO [46]. The secondary loss of dystrophin-associated nNOS was confirmed in *mdx* TA via immunolabelling. Concurrently, we have demonstrated that both basal- and contraction-induced GU in both *mdx* UNSUPP EDL and SOL is comparable to CON. We have demonstrated in our study that NITR increases contraction-induced GU in CON EDL but has no effect in CON SOL. Indeed, we have shown previously that there are greater effects of NOS inhibition on EDL than SOL [46], likely because of a greater comparative nNOS expression in fast-twitch versus slow-twitch muscles [46, 60] and the higher antioxidant enzymes in slow-twitch muscles which may buffer the effects of NO [61]. In both CON EDL and SOL muscles, however, NITR did not affect basal GU rate. This could infer that the NITR dosage administered in our study is sufficient to modulate non-cGMP-dependent contraction-induced GLUT-4 mediated GU [62] but perhaps not cGMP-dependent GLUT-1 basal [63] events. A notable limitation of our study is that we did not quantify cGMP levels in EDL and SOL muscles. However, in light of a recent study which demonstrated that even low dose (0.35mM) NITR therapy for ~2 weeks (in comparison to the 1mM NITR dosage for 8 weeks administered in our study) was sufficient to induce ~3-fold increases in cGMP levels

in rat skeletal muscle, this seems unlikely. Rather, basal GU is likely regulated in the first instance by glucose utilisation, thus increasing NO signalling without the normal simultaneous increase in muscle work (and thus glucose utilisation) results in an unchanged basal GU. Unexpectedly and in contrast to CON EDL, NITR reduced basal GU in *mdx* EDL and SOL. Taken with the fact that NITR stimulated contraction-induced GU in CON but further depressed it in *mdx* muscle, our data suggests that NITR-derived NO is being diverted away from its bio-modulatory effects on GU. Presumably, this is because in *mdx* muscle, in which O_2^- production is notoriously increased [59], NITR-generated NO is being sequestered into ONOO⁻ production instead of cGMP activation, thus reducing the proportional NO available to GU signalling. despite an increased NITR-nitrite-NO pool.

We have assessed various indices of mitochondrial respiratory function in permeabilised red (RG) and white (WG) gastrocnemius fibre bundles. Permeabilisation of intact muscle bundles and delivery of optimal substrate concentrations allows for the measurement of the mitochondrial capacity independent of substrate delivery capacity. Indeed, even in this optimised environment, we demonstrate a reduced capacity (up to 25% of CON) to phosphorylate ADP in both WG and RG from the *mdx* mouse. This is consistent with others [64, 65] who have reported similar depressions in ADP-stimulated phosphorylating respiration in *mdx* skeletal muscle fibres. NITR did not improve phosphorylating or maximal uncoupled respiration in either CON or *mdx* skeletal muscle but did decrease CIV activity in both CON and *mdx* RG. CIV inhibition is an established effect of reversible competitive binding of NO to heme-copper sites *in lieu* of O_2 on CIV, in addition to CI and CIII [66, 67, 68]. Despite the inhibitory effect of NITR on CIV activity and therefore ETS respiratory capacity, the lack of effect on phosphorylating and maximal uncoupled respiration was unexpected, since NITR has been previously shown to improve various mitochondrial properties through stimulation of mitochondrial biogenesis and improved coupling of O_2 consumption to ATP production [37]. Since NO is a highly reactive molecule that, to exert its biological role, must be produced in close proximity to its effector targets, the

exogenous NO source afforded by NITR supplementation in our study may not be penetrating the muscle fibres sufficiently, or in sufficient concentration, to modulate mitochondrial function. This is particularly true of the mitochondrial function governed by nuclear gene regulation such as mitochondrial biogenesis and uncoupling. Aquilano *et al.* [69], for instance, have demonstrated that the loss of nNOS-generated NO production nearby the nucleus is a causative factor of the impairment of mitochondrial biogenesis in skeletal muscle. Thus, while we have evidence of NITR-derived NO penetrating the mitochondria to induce regulatory adaptations such as inhibition of CIV activity, overall respiratory capacity which is dictated predominantly by mitochondrial density and coupling is seemingly unaffected, even in CON mice. This is likely due to the chronic supplementation period and particular dosage employed in our study. For example, similar to our study, Hezel *et al.* [70] did not observe any changes in mitochondrial parameters following 17 months of NITR supplementation in healthy mice. In contrast, others have shown beneficial mitochondrial modulation following much shorter supplementation periods [37, 71]. Ashmore *et al.* [38] have recently demonstrated that NITR dosage is also important to the control of the nuclear signalling of mitochondrial biogenesis in which low (0.35mM), medium (0.7mM) and high (1.4mM) dose NITR therapy (for 15-18 days) in rats had differential effects on PPAR $\alpha/\beta/\delta$ signalling, PGC-1 α expression, citrate synthase activity and mitochondrial fatty acid oxidation. These data highlight that the promotion of mitochondrial biogenesis might be an acute, dose-specific response to shorter-term increases in skeletal muscle NO signalling which may switch off or become desensitised in response to more chronic, prolonged increases in NO production.

The reduced capacity for *mdx* skeletal muscle to phosphorylate ADP and to ramp up respiration during times of metabolic stress may be reflective of uncoupled respiration. In our study, state 4 respiration was significantly less in both WG and RG of *mdx* mice and the RCR was lower in *mdx* RG respiring on CI+II substrates highlighting that respiratory control is compromised in the muscle that is most dependent upon mitochondrial oxidative

ATP production (i.e. red oxidative muscle). When considered in context of a depressed state 3 and 4 respiration, tighter respiratory control would be required to maintain the $\Delta\Psi$ and drive for ATP synthesis, especially given the heightened energy requirements of dystrophic muscle. Indeed, our observations of a depolarised $\Delta\Psi$ in isolated *mdx* mitochondria (C.A. Timpani, A. Hayes and E. Rybalka, unpublished observations) indicate insufficient coupling to maintain the drive for ATP synthesis in red muscle at least. Intriguingly, NITR decreased the RCR only in *mdx* muscles, indicative of mitochondrial uncoupling. Uncoupling may be a beneficial adaptation to ETS dysfunction, to prevent potential hyperpolarisation of the $\Delta\Psi$ which is an initiator of mitochondria-mediated apoptosis [72]. Certainly, the role of NITR-derived NO in the regulation of mitochondrial coupling efficiency is unclear since some studies have demonstrated an enhanced coupling efficiency of human skeletal muscle [37] while others have shown a reduced coupling efficiency of rodent skeletal muscle [38]. Despite the obvious species differences between these studies, these data highlight that NITR-derived NO has a modulatory role on the expression of uncoupling protein 3 (through increased PPAR- α activation [38]) and adenine nucleotide translocase expression, and seemingly regulates the leakiness of several respiratory complexes – all of which contribute to the coupled state of skeletal muscle mitochondria. However, this role requires further elucidation.

A reduced mitochondrial pool (particularly viable mitochondria) could also explain the decreased OXPHOS capacity of dystrophic skeletal muscle in our study. We saw no genotype or muscle-specific differences in CS activity (a marker of mitochondrial density) in our study, however we did see differential expression of ETC complex proteins in *mdx* RG and WG whereby complex proteins generally decreased in RG but increased in WG. This suggests a reduced respiratory capacity despite increased/unchanged mitochondrial density in *mdx* RG in particular. We [23] and others [22, 64, 73] have previously reported this, highlighting that a reduced mitochondrial functional and/or physical density does not account for the decreased mitochondrial respiration associated with dystrophin-deficiency but rather,

that the mitochondrial pool is intrinsically defective. While NITR had no effect on complex expression in RG from either strain, most complexes (except CIV), were upregulated in NITR-supplemented CON but not NITR-supplemented *mdx* WG. In fact, the only observed effect of NITR in WG that was consistent across strains was an increased CS activity, and this was reproducible in the RG from *mdx* but not CON mice. Our finding is curious since Ashmore *et al.* demonstrated that a high (1.4 mM) NITR diet increases CS activity in red SOL muscle from healthy rats, albeit a low (0.35mM) and medium (0.7mM) diet did not [38]. In context, we supplemented our mice with 1mM NITR. Our data thus suggests that there are variations in the response of different fibre types to NITR-derived NO dosages, in which type II fibres are more responsive to a lower NO concentration. Irrespective, changes in mitochondrial CS activity and ETC complex expression induced by NITR did not translate to improved mitochondrial respiration in either CON or *mdx* muscles in our study.

We found in various respiratory states that NITR reduced H₂O₂ production in *mdx* but not CON skeletal muscle. This would immediately seem to be beneficial, as ROS production is elevated in dystrophic muscle [59] and NO reduces oxidative stress at the level of the ETS [74]. However, excessive NO can lead to the generation of RNS in the presence of O₂⁻. In addition to the inhibition of CIV, NO inhibits electron transfer at CI and CIII of the ETS [75], producing O₂⁻ anions that interact with NO to produce ONOO⁻ which can induce cellular damage [76]. In our study, we have demonstrated elevated nitrotyrosine content in *mdx* TA muscles, which is consistent with increased ONOO⁻ production, and this was dramatically exacerbated by NITR (2775% increase). Nitrotyrosine labelling corresponded with an increased area of damage in NITR-supplemented *mdx* TA sections. In previous studies, NO donor therapy has been shown to reduce the area of damage in dystrophic muscle, but as NO donors are typically given in combination with anti-inflammatories [29, 33], our data suggests that the anti-inflammatory component of these co-compounds is perhaps the more pertinent effector. NITR also increased the proportion of centronucleated fibres in *mdx* muscles, which has been previously observed with NO donors [29, 30] and is reflective of an

enhanced regenerative capacity in response to NITR-induced damage. NO is a known stimulator of satellite cell proliferation, which is crucial to skeletal muscle regeneration following damage [77] and is notably defective in dystrophin-deficient muscle [78, 79]. Since dystrophic muscle is in a state of enhanced oxidative stress superfluous NITR-derived NO bioavailability appears detrimental to dystrophic muscle by promoting excess ONOO⁻ formation which, in turn, may exceed antioxidant buffering capacity to promote muscle damage and escalate pathology. This effect may be more evident in predominantly white fast-twitch glycolytic muscles (such as TA) due to the lower endogenous antioxidant content and therefore NO handling capacity, however further investigation is required to elucidate if this is true. It is also possible that the absence of nNOS protein expression, its translocational capacity to deliver NO to specific intracellular sites and the metabolic modulatory effects it exerts, may account for the deleterious effect that NITR had on dystrophic muscle histopathology in our study, since breeding transgenic overexpressing nNOS mice with the *mdx* strain results in significant improvements to dystrophic muscle architecture [26, 27]. NITR therapy, however, might be beneficial for the stimulation of satellite cell replication and dystrophic skeletal muscle regeneration as we observed elevated presence of DAPI-positive nuclei in NITR-treated *mdx* TA. While we did not stain for Pax-7 (a satellite cell marker), we did label CD45+ immune cell infiltrate and IgG deposition within the muscle cross-sections – neither of these measures were affected by NITR SUPP suggesting that the NITR-dependent increase in nuclei content is most likely reflective of an enhanced satellite cell pool. Therefore NITR therapy could be beneficial especially if mitochondrial O₂⁻ production could be pharmacologically attenuated and RNS-induced damage prevented (such as with antioxidant therapy).

In summary, our study is the first to demonstrate that an 8 week supplementation regimen of NITR in drinking water cannot overcome the metabolic dysfunction observed in the *mdx* mouse model of DMD. We are the first to examine contraction-induced GU in the *mdx* model and to demonstrate that NITR supplementation reduces otherwise normal GU in

mdx muscles and cannot positively modulate mitochondrial function. Although NITR supplementation reduced mitochondrial H₂O₂ emission, it induced mitochondrial uncoupling in RG, increased muscle fibre nitrosylation (and therefore ONOO⁻ radicals) and promoted skeletal muscle damage. Our data is consistent with recent literature linking NO to muscle soreness [80]. Together this suggests that enhancing endogenous NO production via exogenous NITR therapy is contraindicated for the treatment of DMD. This is potentially due to the fact that there is no concomitant increase in nNOS protein expression and its regulatory role over metabolic flux control, and, that excessive ROS promotes RNS production which actually reduced NO bioavailability.

There were some limitations to our study that are worthy of mention. In the first instance, we did not quantify cGMP levels in EDL and SOL muscles, and thus cannot confirm that in the presence of heightened O₂⁻ production, NO is diverted away from intracellular signalling pathways (i.e. cGMP production, nucleus signalling of mitochondrial biogenesis) and into RNS formation. This was because whole EDL and SOL was required for our primary measure being radioactive GU, and that our other tissues were not immediately snap frozen, thus cGMP was heavily degraded beyond detectable levels. Secondly, while simultaneous measurement of O₂ flux and H₂O₂ emission has previously been well characterised and reported [51, 52, 53], a potential limitation of this assay is that the supra-physiological chamber pO₂ used to overcome O₂ diffusion limitations of permeabilized muscle fibre preparations, may lead to non-physiological rates of H₂O₂ emission [81]. Therefore, it should be acknowledged that the H₂O₂ measured using the present assay may not completely recapitulate *in vivo* mitochondrial ROS emission rates.

Our data is in stark contrast to previous findings of significant improvements in the dystrophic condition following NO donor therapy, and in Becker patients following nitrite supplementation, suggesting that long-term NITR/NO supplementation requires better characterisation, particularly in conditions of heightened oxidative and/or metabolic stress such as in DMD. While the precise myopathological mechanisms of NITR has not been fully

685 elucidated in the present study, our data is of particular importance considering NITR
686 therapy is currently in clinical trials for the treatment of DMD patients.

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

Table 1. Weights of EDL and SOL used in GU experimentation.

	Left EDL (mg)	Right EDL (mg)	Left SOL (mg)	Right SOL (mg)
CON UNSUPP	12.3 ± 0.8	12.4 ± 1.2	9.0 ± 0.9	9.8 ± 0.9
CON NITR	11.3 ± 0.3	12.6 ± 0.8	10.3 ± 0.5	10.3 ± 0.6
<i>mdx</i> UNSUPP	14.8 ± 0.8####	15.5 ± 1.4####	13.5 ± 1.3####	14.9 ± 1.4####
<i>mdx</i> NITR	14.7 ± 0.9####	16.0 ± 0.8####	13.7 ± 0.8####	13.3 ± 0.6####

Irrespective of supplementation, both EDL and SOL weight were significantly higher in *mdx* mice compared to CON mice. There was no effect of NITR. #### Significant difference from CON mice $p < 0.0001$. CON UNSUPP $n=14$; CON NITR $n=16$; *mdx* UNSUPP $n=12$; *mdx* NITR $n=13$.

Table 2. Weights of the left gastrocnemius used in mitochondrial respiration experimentation, determination of CS activity and western blotting of mitochondrial complexes and the right TA used for immunohistochemistry.

	Gastrocnemius (mg)	TA (mg)
CON UNSUPP	145.18 ± 4.4	46.9 ± 1.7
CON NITR	145.2 ± 3.3	46.5 ± 1.5
<i>mdx</i> UNSUPP	169.9 ± 4.2####	68.9 ± 2.1####
<i>mdx</i> NITR	170.2 ± 4.5####	66.9 ± 4.3####

Irrespective of supplementation, gastrocnemius was significantly higher in *mdx* mice compared to CON mice. There was no effect of NITR. Similarly, TA was significantly higher

718 in *mdx* mice compared to CON mice with no effect of NITR observed in either strain. ####
719 Significant difference from CON mice $p<0.0001$. CON UNSUPP $n=13$; CON NITR $n=16$;
720 *mdx* UNSUPP $n=12$; *mdx* NITR $n=13$.

721 **Abbreviations**

722 ADP: adenosine diphosphate; ATP: adenosine triphosphate; Ca^{2+} : calcium; cGMP: cyclic
723 guanosine monophosphate; CI-V: mitochondrial ETS complexes I-V; CS: citrate synthase;
724 CON: control c57BL/10 (mouse); DMD: Duchenne Muscular Dystrophy; EDL: extensor
725 Digitorum longus; ETS: electron transport system; GLUT: glucose transporter; GU: glucose
726 uptake; *mdx*: muscular dystrophy x-linked on c57BL/10 background (mouse); H_2O_2 :
727 hydrogen peroxide; NaNO_3 : sodium nitrate; NITR: nitrate; nNOS: neuronal nitric oxide
728 synthase; NO: nitric oxide; O_2^- : oxygen; $\text{O}_2^{\cdot-}$: superoxide; ONOO $^-$: peroxynitrite; PFK:
729 phosphofructokinase; PGC1- α : PPAR γ -coactivator 1 α ; PKG: cGMP-regulated protein
730 kinase; PPAR: peroxisome proliferator-activated receptor; RCR: respiratory control ratio;
731 RNS: reactive nitrogen species; ROS: reactive oxygen species; SOL: soleus; TA: tibialis
732 anterior; TCA: tricarboxylic acid; WG: white gastrocnemius.

733 **Acknowledgements**

734 This study was funded by the Victoria University Research Development Grant Scheme
735 (RDGS 15/11: Rybalka, McConell & Hayes).

736

737 **Conflict of Interest**

738 The authors declare no conflict of interest.

739

740

741

Figure Legends

Fig 1. Body weight and average food and water consumption of unsupplemented and NITR-supplemented mice over the supplementation period. Changes in body weight are shown as a percentage of pre-supplementation weight (A). Overall, *mdx* mice gained more weight over the 8 week supplementation period compared to CON ($p<0.0001$, A). NITR had no effect on *mdx* weight gain but did increase weight gain in CON compared to CON UNSUPP ($p<0.05$). Over the 8 week supplementation period, food (B) and water consumption (C) did not differ between unsupplemented and supplemented animals ($p>0.05$) except for food consumption during week two where CON UNSUPP consumed more than all groups ($p<0.05$). CON UNSUPP $n=16$; CON NITR $n=17$; *mdx* UNSUPP $n=14$; *mdx* NITR $n=18$.

Fig 2. GU in isolated EDL and SOL from unsupplemented and NITR supplemented CON and *mdx* mice. In all groups, contraction-induced GU significantly compared to basal conditions ($p<0.05$, A). NITR increased contraction-induced GU in CON EDL ($p<0.05$) but in contrast, reduced both basal- and contraction-induced GU in *mdx* EDL ($p<0.05$). For the SOL, both basal- and contraction-induced GU (B) were comparable ($p>0.05$). NITR reduced basal GU in *mdx* SOL ($p<0.05$) but had no effect in CON SOL. CON UNSUPP $n=9-13$; CON NITR $n=11$; *mdx* UNSUPP $n=11$; *mdx* NITR $n=10-12$.

Fig 3. Mitochondrial function in intact, permeabilised muscle fibres from the white and red portion of gastrocnemius from unsupplemented and NITR-supplemented CON and *mdx* mice. State 4 leak respiration (A) is significantly reduced in *mdx* compared to CON WG, irrespective of substrate combination ($p<0.05$). ADP-stimulated state 3 respiration (A) is significantly reduced in *mdx* compared to CON WG ($p<0.05$) with NITR having no effect. FCCP-stimulated uncoupled respiration (A) is significantly reduced in *mdx* WG compared

with CON ($p<0.05$) with no difference in CIV activity detected between CON and *mdx* WG ($p>0.05$). The respiratory control ratio (RCR; B), an indicator of the coupling of O₂ consumption and ATP production at the ETS, was comparable between CON and *mdx* WG, although a trend for *mdx* to be lower was detected ($p=0.083$). When respiring on CI+II-substrates, the RCR was significantly lower across all groups ($p<0.0001$). State 4 leak respiration (C) is significantly reduced in *mdx* compared to CON RG, irrespective of substrate combination ($p<0.01$). ADP-stimulated state 3 respiration (C) is significantly reduced in *mdx* compared to CON RG ($p<0.001$) with NITR having no effect on phosphorylating respiration. FCCP-stimulated uncoupled respiration (C) is significantly reduced in *mdx* compared with CON ($p<0.001$). CIV activity (C) is significantly reduced in *mdx* UNSUPP compared to CON UNSUPP ($p<0.01$) with NITR inducing a significant decrease in both CON and *mdx* ($p<0.01$). The RCR (D) in *mdx* RG during CI+II-stimulated respiration is lower compared to CON ($p<0.0001$) with NITR decreasing the RCR in *mdx* during CI+II-stimulated respiration ($p<0.001$ respectively). CON UNSUPP $n=12-13$; CON NITR $n=12-13$; *mdx* UNSUPP $n=10-11$; *mdx* NITR $n=11-12$.

Fig 4. Mitochondrial respiratory chain complex proteins, and citrate synthase activity, from the white portion of gastrocnemius from unsupplemented and NITR-supplemented CON and *mdx* mice. In *mdx* UNSUPP WG, expression of CII ($p<0.05$; B), CIII ($p<0.01$; C), CIV ($p<0.05$; D) and CV ($p<0.01$; E) were greater compared to CON UNSUPP. NITR induced an increase in CI ($p<0.01$; A), CII ($p<0.01$; B), CIII ($p<0.05$; C) and CV ($p<0.05$; E) subunits in CON WG but not in *mdx* WG. NITR also increased CS activity (F) in both CON and *mdx* WG ($p<0.05$) with a trend for CS activity to be higher in *mdx* UNSUPP compared to CON ($p=0.07$). Representative western blots of proteins from each of the five mitochondrial respiratory complexes (G) with coomassie blue stains of the respective western blots to demonstrate equal loading of the total protein (H). $n= 8$ per group.

Fig 5. Mitochondrial respiratory chain complex proteins, and citrate synthase activity, from the red portion of gastrocnemius from unsupplemented and NITR supplemented CON and *mdx* mice. Overall, expression of CI, CIII, CIV and CV subunits were decreased in *mdx* RG compared to CON ($p<0.05$; A, C, D, E respectively). NITR increased CS activity in *mdx* RG but not in CON ($p<0.05$; F). Representative western blots of proteins from each of the five mitochondrial respiratory complexes (G) with coomassie blue stains of the respective western blots to demonstrate equal loading of the total protein (H). $n=8$ per group.

Fig 6. H_2O_2 emission in intact fibres from the white (A) and red (B) portions of gastrocnemius from unsupplemented and NITR-supplemented CON and *mdx* mice. In WG, NITR induced a decreased H_2O_2 emission during state 4 leak respiration (A) in CON during CI-stimulated respiration and in both CON and *mdx* during CI+II-stimulated respiration ($p<0.05$). In WG, no significant difference was detected in H_2O_2 emission during ADP-stimulated state 3 respiration (A). There was no significant difference in H_2O_2 emission during FCCP-stimulated uncoupled respiration (A) in WG. In RG (B), NITR induced a decrease in H_2O_2 emission during state 4 leak respiration in *mdx* muscle during CI+II-stimulated respiration ($p<0.001$). In *mdx* RG (B), H_2O_2 emission during ADP-stimulated state 3 respiration was significantly less compared to CON WG ($p<0.05$) with NITR having no effect ($p>0.05$). While there was no differences in H_2O_2 emission during FCCP respiration between CON UNSUPP and *mdx* UNSUPP RG ($p>0.05$, B), NITR reduced H_2O_2 emission in *mdx* RG compared to *mdx* UNSUPP ($p<0.05$). CON UNSUPP $n=12-13$; CON NITR $n=12-13$; *mdx* UNSUPP $n=10-11$; *mdx* NITR $n=11-12$.

Fig 7. Immunohistological analysis of TA from unsupplemented and NITR supplemented CON and *mdx* mice. Nitrotyrosine expression was higher in *mdx* TA compared to CON ($p<0.0001$, A) with NITR supplementation elevating nitrotyrosine

expression in both CON ($p<0.05$) and *mdx* ($p<0.0001$). Nuclei content was higher in *mdx* TA compared to CON ($p<0.0001$, B) with NITR further increasing nuclei content in *mdx* TA ($p<0.0001$). CD45 infiltration (C) and IgG staining (D) was elevated in *mdx* TA compared to CON ($p<0.001$ and $p<0.01$ respectively) and NITR supplementation had no effect in either CON or *mdx* TA ($p>0.05$). Scale bars= 100 μ m. CON UNSUPP $n=3-4$; CON NITR $n=3-4$; *mdx* UNSUPP $n=3-4$; *mdx* NITR $n=3-4$.

Fig 8. Histological analysis of TA from unsupplemented and NITR supplemented CON and *mdx* mice. The frequency histogram (A) indicates an increase in fibre size of *mdx* TA with fibres more frequent from 6000-12000 μ m ($p<0.0001$). NITR had no effect on the distribution of CON or *mdx* fibres but there was a trend for an increased number of fibres around 6000 μ m ($p=0.068$). Mean fibre size (C) was significantly greater in *mdx* TA ($p<0.01$) with a trend for NITR to increase fibre size in *mdx* TA ($p=0.093$). Damaged area (D) and percentage of centronucleated fibres (E) was significantly higher in *mdx* TA ($p<0.01$ and $p<0.0001$ respectively) with NITR stimulating further damage and regeneration ($p<0.01$). CON UNSUPP $n=11$; CON NITR $n=12$; *mdx* UNSUPP $n=11$; *mdx* NITR $n=10$.

References

1. Monaco AP, Bertelson CJ, Middlesworth W, Colletti C-A, Aldridge J, Fischbeck KH, et al. Detection of deletions spanning the Duchenne muscular dystrophy locus using a tightly linked DNA segment. *Nature*. 1985;316(6031):842-5.
2. Emery A. Population frequencies of inherited neuromuscular diseases--a world survey. *Neuromuscular disorders: NMD*. 1991;1(1):19.
3. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell*. 1987;51(6):919-28.
4. Heslop L, Morgan JE, Partridge TA. Evidence for a myogenic stem cell that is exhausted in dystrophic muscle. *Journal of Cell Science*. 2000;113(12):2299-308.
5. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. *Neuromuscular Disorders*. 2002;12(10):926-9.

6. Timpani CA, Hayes A, Rybalka E. Revisiting the dystrophin-ATP connection: How half a century of research still implicates mitochondrial dysfunction in Duchenne Muscular Dystrophy aetiology. *Medical Hypotheses*. 2015;85(6):1021-33.
7. Ohlendieck K, Campbell KP. Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice. *The Journal of Cell Biology*. 1991;115(6):1685-94.
8. Brenman JE, Chao DS, Xia H, Aldape K, Brecht DS. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. *Cell*. 1995;82(5):743-52.
9. Chang WJ, Iannaccone ST, Lau KS, Masters BS, McCabe TJ, McMillan K, et al. Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. *Proceedings of the National Academy of Sciences*. 1996;93(17):9142-7.
10. McConell GK, Rattigan S, Lee-Young RS, Wadley GD, Merry TL. Skeletal muscle nitric oxide signaling and exercise: a focus on glucose metabolism. *American Journal of Physiology - Endocrinology and Metabolism*. 2012;303(3):E301-E7.
11. Leary SC, Battersby BJ, Hansford RG, Moyes CD. Interactions between bioenergetics and mitochondrial biogenesis. *Biochimica et Biophysica Acta (BBA) - Bioenergetics*. 1998;1365(3):522-30.
12. Thomas GD, Sander M, Lau KS, Huang PL, Stull JT, Victor RG. Impaired metabolic modulation of α -adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. *Proceedings of the National Academy of Sciences*. 1998;95(25):15090-5.
13. Vaghy PL, Fang J, Wu W, Vaghy LP. Increased caveolin-3 levels in mdx mouse muscles. *FEBS letters*. 1998;431(1):125-7.
14. Judge LM, Haraguchin M, Chamberlain JS. Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex. *Journal of cell science*. 2006;119(8):1537-46.
15. Kameya S, Miyagoe Y, Nonaka I, Ikemoto T, Endo M, Hanaoka K, et al. α 1-syntrophin gene disruption results in the absence of neuronal-type nitric-oxide synthase at the sarcolemma but does not induce muscle degeneration. *Journal of Biological Chemistry*. 1999;274(4):2193-200.
16. Li D, Yue Y, Lai Y, Hakim CH, Duan D. Nitrosative stress elicited by nNOS μ delocalization inhibits muscle force in dystrophin-null mice. *The Journal of pathology*. 2011;223(1):88-98.
17. Gücüyener K, Ergenekon E, Erbas D, Pinarli G, Serdaroğlu A. The serum nitric oxide levels in patients with Duchenne muscular dystrophy. *Brain and Development*. 2000;22(3):181-3.
18. Kasai T, Abeyama K, Hashiguchi T, Fukunaga H, Osame M, Maruyama K. Decreased total nitric oxide production in patients with Duchenne muscular dystrophy. *Journal of biomedical science*. 2004;11(4):534-7.
19. Barton ER, Morris L, Kawana M, Bish LT, Toursel T. Systemic administration of L-arginine benefits mdx skeletal muscle function. *Muscle & Nerve*. 2005;32(6):751-60.
20. Wehling-Henricks M, Oltmann M, Rinaldi C, Myung KH, Tidball JG. Loss of positive allosteric interactions between neuronal nitric oxide synthase and phosphofructokinase contributes to defects in glycolysis and increased fatigability in muscular dystrophy. *Human Molecular Genetics*. 2009;18(18):3439-51.
21. Vignos Jr PJ, Lefkowitz M. A biochemical study of certain skeletal muscle constituents in human progressive muscular dystrophy. *Journal of Clinical Investigation*. 1959;38(6):873.
22. Chi MMY, Hintz CS, McKee D, Felder S, Grant N, Kaiser KK, et al. Effect of Duchenne muscular dystrophy on enzymes of energy metabolism in individual muscle fibers. *Metabolism*. 1987;36(8):761-7.
23. Rybalka E, Timpani CA, Cooke MB, Williams AD, Hayes A. Defects in Mitochondrial ATP Synthesis in Dystrophin-Deficient Mdx Skeletal Muscles May Be Caused by Complex I Insufficiency. *PloS one*. 2014;9(12):e115763.
24. Austin L, De Niese M, McGregor A, Arthur H, Gurusinghe A, Gould M. Potential oxyradical damage and energy status in individual muscle fibres from degenerating muscle diseases. *Neuromuscular Disorders*. 1992;2(1):27-33.

25. Cole M, Rafael J, Taylor D, Lodi R, Davies K, Styles P. A quantitative study of bioenergetics in skeletal muscle lacking utrophin and dystrophin. *Neuromuscular Disorders*. 2002;12(3):247-57.
26. Wehling M, Spencer MJ, Tidball JG. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. *The Journal of Cell Biology*. 2001;155(1):123-32.
27. Tidball JG, Wehling-Henricks M. Expression of a NOS transgene in dystrophin-deficient muscle reduces muscle membrane damage without increasing the expression of membrane-associated cytoskeletal proteins. *Molecular genetics and metabolism*. 2004;82(4):312-20.
28. Voisin V, Sebric C, Matecki S, Yu H, Gillet B, Ramonatxo M, et al. L-arginine improves dystrophic phenotype in mdx mice. *Neurobiology of disease*. 2005;20(1):123-30. Epub 2005/09/03.
29. Brunelli S, Sciorati C, D'Antona G, Innocenzi A, Covarello D, Galvez BG, et al. Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. *Proceedings of the National Academy of Sciences*. 2007;104(1):264-9.
30. Mizunoya W, Upadhaya R, Burczynski FJ, Wang G, Anderson JE. Nitric oxide donors improve prednisone effects on muscular dystrophy in the mdx mouse diaphragm. *2011-05-01 00:00:00*. C1065-C77 p.
31. Vianello S, Consolaro F, Bich C, Cancela J-M, Roulot M, Lanchec E, et al. Low doses of arginine butyrate derivatives improve dystrophic phenotype and restore membrane integrity in DMD models. *The FASEB Journal*. 2014;28(6):2603-19.
32. Archer JD, Vargas CC, Anderson JE. Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. *The FASEB Journal*. 2006.
33. Uaesoontrachoon K, Quinn JL, Tatem KS, Van Der Meulen JH, Yu Q, Phadke A, et al. Long-term treatment with naproxen significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. *Human Molecular Genetics*. 2014;23(12):3239-49.
34. Thomas GD, Ye J, De Nardi C, Monopoli A, Ongini E, Victor RG. Treatment with a Nitric Oxide-Donating NSAID Alleviates Functional Muscle Ischemia in the Mouse Model of Duchenne Muscular Dystrophy. *PLoS ONE*. 2012;7(11):e49350.
35. Anderson JE, Vargas C. Correlated NOS- μ and myf5 expression by satellite cells in mdx mouse muscle regeneration during NOS manipulation and deflazacort treatment. *Neuromuscular Disorders*. 2003;13(5):388-96.
36. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. *Nat Rev Drug Discov*. 2008;7(2):156-67.
37. Larsen FJ, Schiffer TA, Borniquel S, Sahlin K, Ekblom B, Lundberg JO, et al. Dietary inorganic nitrate improves mitochondrial efficiency in humans. *Cell metabolism*. 2011;13(2):149-59.
38. Ashmore T, Roberts LD, Morash AJ, Kotwica AO, Finnerty J, West JA, et al. Nitrate enhances skeletal muscle fatty acid oxidation via a nitric oxide-cGMP-PPAR-mediated mechanism. *BMC biology*. 2015;13(1):1.
39. Bailey SJ, Winyard P, Vanhatalo A, Blackwell JR, DiMenna FJ, Wilkerson DP, et al. Dietary nitrate supplementation reduces the O₂ cost of low-intensity exercise and enhances tolerance to high-intensity exercise in humans. *Journal of Applied Physiology*. 2009;107(4):1144-55.
40. Larsen F, Weitzberg E, Lundberg J, Ekblom B. Effects of dietary nitrate on oxygen cost during exercise. *Acta physiologica*. 2007;191(1):59-66.
41. Bailey SJ, Fulford J, Vanhatalo A, Winyard PG, Blackwell JR, DiMenna FJ, et al. Dietary nitrate supplementation enhances muscle contractile efficiency during knee-extensor exercise in humans. *Journal of Applied Physiology*. 2010;109(1):135-48.
42. Kenjale AA, Ham KL, Stabler T, Robbins JL, Johnson JL, VanBruggen M, et al. Dietary nitrate supplementation enhances exercise performance in peripheral arterial disease. *Journal of applied physiology*. 2011;110(6):1582-91.
43. Nelson MD, Rosenberry R, Barresi R, Tsimerinov EI, Rader F, Tang X, et al. Sodium nitrate alleviates functional muscle ischaemia in patients with Becker muscular dystrophy. *The Journal of physiology*. 2015;593(23):5183-200.

953 44. Carlström M, Larsen FJ, Nyström T, Hezel M, Borniquel S, Weitzberg E, et al. Dietary
954 inorganic nitrate reverses features of metabolic syndrome in endothelial nitric oxide synthase-
955 deficient mice. *Proceedings of the National Academy of Sciences*. 2010;107(41):17716-20.

956 45. Hernández A, Schiffer TA, Ivarsson N, Cheng AJ, Bruton JD, Lundberg JO, et al. Dietary nitrate
957 increases tetanic $[Ca^{2+}]_i$ and contractile force in mouse fast-twitch muscle. *The Journal of*
958 *physiology*. 2012;590(15):3575-83.

959 46. Merry TL, Steinberg GR, Lynch GS, McConell GK. Skeletal muscle glucose uptake during
960 contraction is regulated by nitric oxide and ROS independently of AMPK. *American Journal of*
961 *Physiology-Endocrinology and Metabolism*. 2010;298(3):E577-E85.

962 47. Hong YH, Frugier T, Zhang X, Murphy RM, Lynch GS, Betik AC, et al. Glucose uptake during
963 contraction in isolated skeletal muscles from neuronal nitric oxide synthase μ knockout mice. *Journal*
964 *of Applied Physiology*. 2015;118(9):1113-21.

965 48. Goodman CA, Horvath D, Stathis C, Mori T, Croft K, Murphy RM, et al. Taurine
966 supplementation increases skeletal muscle force production and protects muscle function during
967 and after high-frequency in vitro stimulation. *Journal of Applied Physiology*. 2009;107(1):144-54.

968 49. Stephenson EJ, Stepto NK, Koch LG, Britton SL, Hawley JA. Divergent skeletal muscle
969 respiratory capacities in rats artificially selected for high and low running ability: a role for Nor1?
970 *Journal of applied physiology*. 2012;113(9):1403-12.

971 50. Stephenson EJ, Camera DM, Jenkins TA, Kosari S, Lee JS, Hawley JA, et al. Skeletal muscle
972 respiratory capacity is enhanced in rats consuming an obesogenic Western diet. *American Journal of*
973 *Physiology-Endocrinology and Metabolism*. 2012;302(12):E1541-E9.

974 51. Makrecka-Kuka M, Krumschnabel G, Gnaiger E. High-resolution respirometry for
975 simultaneous measurement of oxygen and hydrogen peroxide fluxes in permeabilized cells, tissue
976 homogenate and isolated mitochondria. *Biomolecules*. 2015;5(3):1319-38.

977 52. Hickey AJ, Renshaw GM, Speers-Roesch B, Richards JG, Wang Y, Farrell AP, et al. A radical
978 approach to beating hypoxia: depressed free radical release from heart fibres of the hypoxia-
979 tolerant epaulette shark (*Hemiscyllium ocellatum*). *Journal of comparative physiology B, Biochemical,*
980 *systemic, and environmental physiology*. 2012;182(1):91-100. Epub 2011/07/13.

981 53. Krumschnabel G, Fontana-Ayoub M, Sumbalova Z, Heidler J, Gauper K, Fasching M, et al.
982 Simultaneous high-resolution measurement of mitochondrial respiration and hydrogen peroxide
983 production. *Methods in molecular biology (Clifton, NJ)*. 2015;1264:245-61. Epub 2015/01/30.

984 54. Larsen S, Nielsen J, Hansen CN, Nielsen LB, Wibrand F, Stride N, et al. Biomarkers of
985 mitochondrial content in skeletal muscle of healthy young human subjects. *The Journal of*
986 *physiology*. 2012;590(14):3349-60.

987 55. Vigelsø Hansen A, Andersen NB, Dela F. The relationship between skeletal muscle
988 mitochondrial citrate synthase activity and whole body oxygen uptake adaptations in response to
989 exercise training. *International journal of physiology, pathophysiology and pharmacology*.
990 2014;6(2):84-101.

991 56. Srere P. [1] Citrate synthase:[EC 4.1. 3.7. Citrate oxaloacetate-lyase (CoA-acetylating)].
992 *Methods in enzymology*. 1969;13:3-11.

993 57. Shavlakadze T, White J, Hoh JF, Rosenthal N, Grounds MD. Targeted expression of insulin-
994 like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice. *Molecular Therapy*.
995 2004;10(5):829-43.

996 58. Larsen S, Nielsen J, Hansen CN, Nielsen LB, Wibrand F, Stride N, et al. Biomarkers of
997 mitochondrial content in skeletal muscle of healthy young human subjects. *The Journal of*
998 *Physiology*. 2012;590(14):3349-60.

999 59. Disatnik MH, Dhawan J, Yu Y, Beal MF, Whirl MM, Franco AA, et al. Evidence of oxidative
1000 stress in *mdx* mouse muscle: Studies of the pre-necrotic state. *Journal of the Neurological*
1001 *Sciences*. 1998;161(1):77-84.

1002 60. Kobzik L, Reid MB, Bredt DS, Stamler JS. Nitric oxide in skeletal muscle. *Nature*.
1003 1994;372(6506):546-8.

61. Ji LL, Fu R, Mitchell EW. Glutathione and antioxidant enzymes in skeletal muscle: effects of fiber type and exercise intensity. *Journal of Applied Physiology*. 1992;73(5):1854-9.
62. Richter EA, Hargreaves M. Exercise, GLUT4, and skeletal muscle glucose uptake. *Physiological reviews*. 2013;93(3):993-1017.
63. Ren J-M, Marshall B, Gulve E, Gao J, Johnson D, Holloszy J, et al. Evidence from transgenic mice that glucose transport is rate-limiting for glycogen deposition and glycolysis in skeletal muscle. *Journal of Biological Chemistry*. 1993;268(22):16113-5.
64. Kuznetsov AV, Winkler K, Wiedemann F, von Bossanyi P, Dietzmann K, Kunz WS. Impaired mitochondrial oxidative phosphorylation in skeletal muscle of the dystrophin-deficient mdx mouse. *Molecular and cellular biochemistry*. 1998;183(1):87-96.
65. Passaquin AC, Renard M, Kay L, Challet C, Mokhtarian A, Wallimann T, et al. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. *Neuromuscular Disorders*. 2002;12(2):174-82.
66. Brown GC, Borutaite V, editors. Nitric oxide, cytochrome c and mitochondria. *Biochemical Society Symposia*; 1999: Portland Press Limited.
67. Brunori M, Giuffrè A, Forte E, Mastronicola D, Barone MC, Sarti P. Control of cytochrome c oxidase activity by nitric oxide. *Biochimica et Biophysica Acta (BBA)-Bioenergetics*. 2004;1655:365-71.
68. Sarti P, Giuffrè A, Barone MC, Forte E, Mastronicola D, Brunori M. Nitric oxide and cytochrome oxidase: reaction mechanisms from the enzyme to the cell. *Free Radical Biology and Medicine*. 2003;34(5):509-20.
69. Aquilano K, Baldelli S, Ciriolo MR. Nuclear recruitment of neuronal nitric-oxide synthase by α -syntrophin is crucial for the induction of mitochondrial biogenesis. *Journal of Biological Chemistry*. 2014;289(1):365-78.
70. Hezel MP, Liu M, Schiffer TA, Larsen FJ, Checa A, Wheelock CE, et al. Effects of long-term dietary nitrate supplementation in mice. *Redox Biology*. 2015.
71. Nisoli E, Falcone S, Tonello C, Cozzi V, Palomba L, Fiorani M, et al. Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. *Proceedings of the National Academy of Sciences of the United States of America*. 2004;101(47):16507-12.
72. Nagy G, Koncz A, Fernandez D, Perl A. Nitric oxide, mitochondrial hyperpolarization, and T cell activation. *Free Radical Biology and Medicine*. 2007;42(11):1625-31.
73. Jongpiputvanich S, Sueblinvong T, Norapucsunton T. Mitochondrial respiratory chain dysfunction in various neuromuscular diseases. *Journal of clinical neuroscience*. 2005;12(4):426-8.
74. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB β). *Science*. 2001;292(5522):1728-31.
75. Poderoso JJ, Carreras C, Lisdero C, Riobó N, Schöpfer F, Boveris A. Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles. *Archives of biochemistry and biophysics*. 1996;328(1):85-92.
76. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. *Proceedings of the National Academy of Sciences*. 1990;87(4):1620-4.
77. Anderson JE. A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells. *Molecular biology of the cell*. 2000;11(5):1859-74.
78. Biressi S, Miyabara EH, Gopinath SD, Carlig PM, Rando TA. A Wnt-TGF β 2 axis induces a fibrogenic program in muscle stem cells from dystrophic mice. *Science translational medicine*. 2014;6(267):267ra176-267ra176.
79. Dumont NA, Wang YX, von Maltzahn J, Pasut A, Bentzinger CF, Brun CE, et al. Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. *Nature medicine*. 2015;21(12):1455-63.

- 1054 80. Radak Z, Naito H, Taylor AW, Goto S. Nitric oxide: Is it the cause of muscle soreness? Nitric
1055 Oxide. 2012;26(2):89-94.
- 1056 81. Hoffman DL, Brookes PS. Oxygen sensitivity of mitochondrial reactive oxygen species
1057 generation depends on metabolic conditions. The Journal of biological chemistry.
1058 2009;284(24):16236-45. Epub 2009/04/16.

1059

1060